Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. (AQST) Revenue
Annual & quarterly revenue history · segment & region breakdown
AQST · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAquestive Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.05B, a decrease of 22.61% year-over-year from $0.04B in FY2025.
Revenue trend
2025 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.04B | -$0.01B | -22.61% |
| 2024-12-31 | $0.06B | +$0.01B | +13.80% |
| 2023-12-31 | $0.05B | +$0.00B | +6.09% |
| 2022-12-31 | $0.05B | -$0.00B | -6.20% |
| 2021-12-31 | $0.05B | +$0.00B | +10.87% |
| 2020-12-31 | $0.05B | -$0.01B | -12.85% |
| 2019-12-31 | $0.05B | -$0.01B | -21.98% |
| 2018-12-31 | $0.07B | +$0.00B | +0.77% |
| 2017-12-31 | $0.07B | +$0.02B | +29.22% |
| 2016-12-31 | $0.05B | — | — |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare AQST revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Aquestive Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Aquestive Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Aquestive Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AQST revenue · 4 questionsAQST's trailing twelve-month (TTM) revenue is $0.05B. That is a decrease of 22.61% year-over-year from $0.04B in FY2025.
▸ Source: FMP · Aquestive Therapeutics, Inc. SEC filings · GAAP · Aquestive Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026